ICBP Impacts, Reports & Infographics
The findings from International Cancer Benchmarking Partnership (ICBP) research have had considerable impact on policy and practice internationally. The collaborative nature of ICBP has led to many instances of knowledge exchange and the adoption of similar practice internationally - such attributes are core to the benefits of the partnership.
To date, the ICBP has provided evidence which has informed cancer plans, evidenced public awareness campaigns, driven innovative new care pathways and improved cancer data completeness across partner jurisdictions. An Impact Report detailing such developments is available below.
The CanStaging+ tool is available at http://canstaging.org providing online (and offline, for limited online-service settings) access to up-to-date rules and standards in a free, intuitive, and open-source software to support better recording and increased completeness and quality of population level staging data. The tool automatically calculations T,M,N stage data based on raw information entered, and will provide a range of stage groups when data entered is limited. In addition to stage group, essential TMN, FIGO, and Dukes calculations can also be provided. Images and flowcharts are available to assist with manual stage classification as well as education.
The ABC tool
The Awareness and Beliefs about Cancer (ABC) questionnaire is an internationally validated tool. The tool was tested in all participating countries with minor variations included to allow for differences in cultural and health systems.
The ABC tool is available for use by interested researchers. Please contact the ICBP Programme Management team (firstname.lastname@example.org) for more information.
Survey to assess factors affecting primary care and cancer diagnosis
As part of the ICBP, researchers at the University of Oxford (United Kingdom) developed an online survey which was used to assess differences in healthcare systems, as well as how physicians respond to patients who present with symptoms within their working environment. This survey has since been carried out in New Zealand.
Further information about the survey is available from the ICBP Programme Management team (email@example.com).
Patient, primary care and treatment specialist surveys
Using validated patient, primary care physician (PCP) and cancer treatment specialists (CTS) questionnaires, ICBP researchers will report the first robust international comparison of time intervals from first symptom(s) until start of treatment.
By asking newly diagnosed patients (3-6 months after diagnosis), PCPs and CTSs about the patient’s journey from symptom onset until treatment, the research team aim to provide new insights into:
- Specific time intervals and details of a patient’s route to diagnosis and treatment.
- The number of times a patient saw a health care professional before diagnosis.
- The nature of any referrals and diagnostic tests carried out.
- Associations between these factors and a range of patient outcomes (including survival and stage at diagnosis).
Below are samples of the survey sent to breast cancer patients, primary care practitioners and cancer treatment specialists in England. Researchers who wish to carry out this survey in their country should first contact the ICBP Programme Management team (firstname.lastname@example.org) as these surveys exist and have been validated in other languages.
Our showcase reports provide an update on progress within the partnership, including findings, the impacts of our research and ongoing studies. These reports provide an overview of the partnership at certain points in time.
ICBP in other publications and communications
ICBP work often feeds in to the work of other organisations, including in publications, blogs and other forms of communications. Here we have provided a selection:
ICBP Country summaries
Phase 1 survival data showed that lung cancer survival in Alberta was generally lower due to limited diagnostic pathways and accessibility. ICBP evidence was since cited to secure funding for an improved diagnostic pathway and two Rapid Access Clinics in Alberta. Whereas patients used to wait up to 190 days from symptom presentation to treatment, today the target has been reduced to 30 days.
- We provided evidence about cancer stage distribution which underpinned a focus on earlier and faster cancer diagnosis. This is important, as it is a shared priority for politicians, policymakers, clinicians and patient advocates.
- The ICBP provided insights for public awareness campaigns and highlighted the impact of social inequalities.
- Our research provided evidence for initiatives in the third (2010) and fourth (2016) National Cancer Action Plans.
- ICBP provided evidence to support the Danish 3-legged strategy, highlighting that primary care practitioners need better and faster access to investigations.
- The ICBP provided new evidence for cancer plans and identified priorities for new initiatives.
- We confirmed evidence underpinning public awareness campaigns.
- We contributed evidence for the ACE (Accelerate, Coordinate, Evaluate) programme, exploring innovative diagnostic referral pathways.
- We provided evidence that underpinned projects improving cancer data completeness and availability.
- Our findings prompted a programme of research into ovarian cancer.
- The ICBP increased engagement within the primary care community on topics related to cancer, particularly differences in referral to specialists.
- We confirmed evidence underpinning Manitoba’s ‘InSixty’ initiative, aimed at reducing the time cancer is first suspected to the time it is treated to 60 days or less.
- We provided a patient voice to the local cancer patient journey initiative, hearing how patients describe their successes and challenges with the system.
- The ICBP provided evidence which underpinned projects improving cancer data completeness and availability.
- Further analyses of ICBP data have been validated by local administrative data, deepening the understanding of the health system.
- We provided evidence to Cancer Care Ontario’s Clinical Council, which develops cancer system strategy and the provincial cancer plan.
New South Wales
- Our evidence underpinned projects improving cancer data completeness and availability.
- Improvements to cancer registry practices were based on findings from the ICBP.
- Our insights informed the choice of cancers with special emphasis in The NSW Cancer Plan (2016-2020).
- ICBP research led to the Northern Ireland Cancer Registry developing a mechanism for hospital admissions data relating to other health conditions (comorbities) to be collected.
- We also provided insights for the ‘Be Cancer Aware’ public awareness campaigns.
- Our evidence supported more user-oriented cancer care, improving diagnostic capacity and early cancer prevention as part of the Norwegian Cancer Plan (2013-2017).
- We provided evidence that confirmed to the Norwegian Board of Health Supervision that late diagnosis is a key issue in cancer care in Norway.
- ICBP-related research provided new evidence for the need for improved and targeted initiatives to enhance public awareness about melanoma.
- The ICBP provided evidence for Scotland’s new cancer strategy ‘Beating Cancer: Ambition and Action (2016)’.
- We provided evidence to the Scottish Primary Care Cancer Group and the Scottish Clinical Imaging Network to improve direct access to imaging for primary care practitioners.
- The ICBP provided evidence towards a major effort to reduce waiting times, with additional funding from the national government.
- Our findings provided a stimulus for a continued focus on improvement around breast cancer.
- ICBP work contributed to the development of a colorectal cancer patient reported experience questionnaire.
- Our research provided insights which initiated discussion about public awareness campaigns.
- Our findings contributed to a renewed assessment of data quality in the Swedish cancer register, in particular around death certificate only cases.
- The ICBP informed the Victorian Cancer Plan (2016-2020).
- Our evidence prompted a review of ovarian cancer treatment practices and the cancer registration process.
- We provided evidence supporting a state-wide implementation of an ovarian cancer optimal care pathway.
- The ICBP contributed to a lung cancer initiative to use a cross pathway approach to improve outcomes.
- Our findings prompted a study tour to Denmark, to learn more about improvements in access to diagnostics. This tour provided additional evidence to set up rapid access to diagnostics pilots in Wales.
- We provided ovarian cancer awareness evidence in Wales, which contributed to the development of the equivalent English regional ‘Be Clear on Cancer’ campaign.